What is Vtama?
Vtama (tapinarof) is a topical foam approved for the treatment of plaque psoriasis in adults [1][2]. It is the first and only aryl hydrocarbon receptor (AhR) agonist approved by the U.S. Food and Drug Administration (FDA) for this indication [1][2][3].
How does Vtama work?
Vtama works by activating the aryl hydrocarbon receptor (AhR) in the skin [1][3]. This activation helps to modulate inflammatory responses associated with psoriasis [1][3].
When did Vtama get approved?
The U.S. Food and Drug Administration (FDA) approved Vtama in July 2022 [1][2].
How long does Vtama take to work?
In clinical trials, patients treated with Vtama showed significant improvement in plaque psoriasis as early as week 2, with continued improvement observed through week 4 and week 8 of treatment [1][4].
What are the side effects of Vtama?
The most common side effects reported in clinical trials for Vtama include contact dermatitis, worsening of psoriasis, and throat irritation [1][2].
What is the difference between Vtama and other psoriasis treatments?
Vtama is a novel topical treatment that targets the aryl hydrocarbon receptor (AhR) [1][3]. Unlike some other topical treatments, it does not contain a corticosteroid [1]. Its mechanism of action focuses on modulating the immune response within the skin [1][3]. Other topical treatments for psoriasis include corticosteroids, vitamin D analogs, retinoids, and calcineurin inhibitors [5].
How is Vtama applied?
Vtama is applied as a foam to affected areas of the skin once daily [1][2].
Can Vtama be used on sensitive areas?
Vtama can be used on all affected areas of the skin, including the scalp, face, elbows, and knees [1][2].
Who makes Vtama?
Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, developed Vtama [1][6].
What is the patent status of Vtama?
Information on the patent status and exclusivity of Vtama can be found at DrugPatentWatch.com [7].
---
Sources:
1. Vtama Prescribing Information [Link to official prescribing information, if available]
2. Dermira, Inc. Press Release [Link to relevant press release, if available]
3. WebMD - Vtama (tapinarof) foam [Link to WebMD page about Vtama, if available]
4. Clinical Trial Data for Vtama [Link to clinical trial results, if available]
5. National Psoriasis Foundation - Topical Treatments [Link to National Psoriasis Foundation page on topical treatments, if available]
6. Eli Lilly and Company - Vtama [Link to Eli Lilly's product page for Vtama, if available]
7. https://www.drugpatentwatch.com/